-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Barclays Raises GoodRx (NASDAQ:GDRX) Price Target to $13.00
Barclays Raises GoodRx (NASDAQ:GDRX) Price Target to $13.00
GoodRx (NASDAQ:GDRX – Get Rating) had its price objective upped by Barclays from $12.00 to $13.00 in a report published on Tuesday, The Fly reports. They currently have an overweight rating on the stock.
GDRX has been the subject of a number of other research reports. Bank of America began coverage on shares of GoodRx in a report on Monday, June 6th. They set a buy rating and a $11.00 price objective for the company. The Goldman Sachs Group cut shares of GoodRx from a buy rating to a neutral rating and reduced their price target for the company from $12.00 to $9.00 in a report on Thursday, June 9th. SVB Leerink cut shares of GoodRx from an outperform rating to a market perform rating and reduced their price target for the company from $33.00 to $10.00 in a report on Tuesday, May 10th. Royal Bank of Canada reiterated a sector perform rating and issued a $6.50 price target (down previously from $8.00) on shares of GoodRx in a report on Thursday, June 23rd. Finally, Robert W. Baird reduced their price target on shares of GoodRx from $7.00 to $6.00 and set a neutral rating for the company in a report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, GoodRx currently has a consensus rating of Hold and an average price target of $16.37.
Get GoodRx alerts:GoodRx Stock Up 2.6 %
Shares of NASDAQ GDRX opened at $7.60 on Tuesday. The stock has a market cap of $3.01 billion, a P/E ratio of -69.09, a P/E/G ratio of 22.62 and a beta of 0.77. The firm has a 50 day moving average price of $6.59 and a 200 day moving average price of $13.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 16.76 and a current ratio of 11.23. GoodRx has a 52-week low of $5.61 and a 52-week high of $48.05.
GoodRx (NASDAQ:GDRX – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.02. The firm had revenue of $191.80 million during the quarter, compared to analysts' expectations of $184.71 million. GoodRx had a negative net margin of 5.86% and a positive return on equity of 2.97%. The business's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 earnings per share. Analysts expect that GoodRx will post 0.02 EPS for the current year.Institutional Trading of GoodRx
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd bought a new stake in GoodRx during the fourth quarter worth $706,000. Parkwood LLC bought a new position in shares of GoodRx in the fourth quarter valued at about $569,000. Darlington Partners Capital Management LP bought a new position in shares of GoodRx in the fourth quarter valued at about $52,276,000. Ardmore Road Asset Management LP bought a new position in shares of GoodRx in the fourth quarter valued at about $1,634,000. Finally, Prospect Capital Advisors LLC bought a new position in shares of GoodRx in the fourth quarter valued at about $7,536,000. 52.60% of the stock is owned by institutional investors.
GoodRx Company Profile
(Get Rating)
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
Featured Articles
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
GoodRx (NASDAQ:GDRX – Get Rating) had its price objective upped by Barclays from $12.00 to $13.00 in a report published on Tuesday, The Fly reports. They currently have an overweight rating on the stock.
据The Fly报道,在周二发布的一份报告中,巴克莱将GoodRx(纳斯达克:GET评级)的目标价从12.00美元上调至13.00美元。他们目前对该股的评级为增持。
GDRX has been the subject of a number of other research reports. Bank of America began coverage on shares of GoodRx in a report on Monday, June 6th. They set a buy rating and a $11.00 price objective for the company. The Goldman Sachs Group cut shares of GoodRx from a buy rating to a neutral rating and reduced their price target for the company from $12.00 to $9.00 in a report on Thursday, June 9th. SVB Leerink cut shares of GoodRx from an outperform rating to a market perform rating and reduced their price target for the company from $33.00 to $10.00 in a report on Tuesday, May 10th. Royal Bank of Canada reiterated a sector perform rating and issued a $6.50 price target (down previously from $8.00) on shares of GoodRx in a report on Thursday, June 23rd. Finally, Robert W. Baird reduced their price target on shares of GoodRx from $7.00 to $6.00 and set a neutral rating for the company in a report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, GoodRx currently has a consensus rating of Hold and an average price target of $16.37.
GDRX已经成为许多其他研究报告的主题。美国银行在6月6日星期一的一份报告中开始报道GoodRx的股票。他们为该公司设定了买入评级和11.00美元的目标价。在6月9日星期四的一份报告中,高盛将GoodRx的股票评级从买入下调至中性,并将该公司的目标价从12.00美元下调至9.00美元。SVB Leerink在5月10日周二的一份报告中将GoodRx的股票评级从表现优于大盘下调至市场表现评级,并将该公司的目标价从33.00美元下调至10.00美元。加拿大皇家银行重申了行业表现评级,并在6月23日周四的一份报告中发布了GoodRx股票的6.50美元目标价(低于之前的8.00美元)。最后,罗伯特·W·贝尔德将GoodRx的股票目标价从7.00美元下调至6.00美元,并在6月22日星期三的一份报告中为该公司设定了中性评级。一名分析师对该股的评级为卖出,12名分析师给出了持有评级,6名分析师给出了该公司股票的买入评级。根据MarketBeat的数据,GoodRx目前的共识评级为持有,平均目标价为16.37美元。
GoodRx Stock Up 2.6 %
GoodRx股价上涨2.6%
Shares of NASDAQ GDRX opened at $7.60 on Tuesday. The stock has a market cap of $3.01 billion, a P/E ratio of -69.09, a P/E/G ratio of 22.62 and a beta of 0.77. The firm has a 50 day moving average price of $6.59 and a 200 day moving average price of $13.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 16.76 and a current ratio of 11.23. GoodRx has a 52-week low of $5.61 and a 52-week high of $48.05.
周二,纳斯达克GDRX的股价开盘报7.6美元。该股市值为30.1亿美元,市盈率为-69.09,市盈率为22.62,贝塔系数为0.77。该公司的50日移动均线价格为6.59美元,200日移动均线价格为13.75美元。该公司的负债权益比率为0.80,速动比率为16.76,流动比率为11.23。GoodRx的52周低点为5.61美元,52周高点为48.05美元。
Institutional Trading of GoodRx
GoodRx的机构交易
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd bought a new stake in GoodRx during the fourth quarter worth $706,000. Parkwood LLC bought a new position in shares of GoodRx in the fourth quarter valued at about $569,000. Darlington Partners Capital Management LP bought a new position in shares of GoodRx in the fourth quarter valued at about $52,276,000. Ardmore Road Asset Management LP bought a new position in shares of GoodRx in the fourth quarter valued at about $1,634,000. Finally, Prospect Capital Advisors LLC bought a new position in shares of GoodRx in the fourth quarter valued at about $7,536,000. 52.60% of the stock is owned by institutional investors.
机构投资者和对冲基金最近增持或减持了该公司的股份。Qube Research&Technologies Ltd在第四季度购买了GoodRx价值70.6万美元的新股份。Parkwood LLC在第四季度购买了GoodRx的新头寸,价值约56.9万美元。Darlington Partners Capital Management LP在第四季度购买了GoodRx的新头寸,价值约52,276,000美元。Ardmore Road Asset Management LP在第四季度购买了GoodRx的新头寸,价值约1,634,000美元。最后,Prospect Capital Advisors LLC在第四季度购买了GoodRx的新头寸,价值约7,536,000美元。52.60%的股票由机构投资者持有。
GoodRx Company Profile
GoodRx公司简介
(Get Rating)
(获取评级)
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
GoodRx Holdings,Inc.通过其子公司提供信息和工具,使消费者能够比较价格并节省在美国购买处方药的费用。该公司运营着一个价格比较平台,为消费者提供经过策划的、与地理位置相关的处方定价,并通过GoodRx代码获得协商价格,这些代码用于在美国各地节省处方费用。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- 免费获取StockNews.com关于GoodRx的研究报告(GDRX)
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗?
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票?
- 迪士尼(NYSE:DIS)的股票刚刚给了投资者一个巨大的信号
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
接受GoodRx Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对GoodRx和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧